Endocrinology

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. A Study to Assess Bone Quality Characteristics, Comparing Type 2 Diabetes Patients who have or have not had Prior Fragile Bone Fractures

   Rochester, Minn.

   The purpose of this study is to assess key characteristics of bone quality, specifically material strength and porosity, in patients who have type 2 diabetes. These patients are at an unexplained increased risk for fractures and there is an urgent need to refine clinical assessment for this risk.

2. A Study to Test How Muscle Tissue Differs Between People

   Rochester, Minn.

   The purpose of this study is to look for ways to test how muscle tissue differs between people.

3. Insulin Regulation of Lipolysis and Lipolysis Proteins

   Rochester, Minn.

   The purpose of this study is to determine whether impaired insulin-induced suppression of lipolysis (as measured by IC50) is related to lipolysis proteins in groups of volunteers known to vary widely with regards to abdominal adipocyte size and regulation of adipose tissue lipolysis, and whether the improved insulin regulation of lipolysis resulting from treatment with the PPARγ agonist pioglitazone, with or without weight loss, can be linked to specific changes in sets of PPARγ-responsive adipocyte lipolysis proteins in UBO adults.
   
   
   
    

    

    

    

    

4. Patient-Centered Exploration to Understand their perception of comprehensive regenerative care

   Rochester, Minn.

   The study purpose is to understand patients’ with the diagnosis of Diabetes Mellitus type 1 or 2 perception of the care they receive in the Diabetes clinic or Diabetes technology clinic at Mayo Clinic and to explore and to identify the healthcare system components patients consider important to be part of the comprehensive regenerative care in the clinical setting.

   However, before we can implement structural changes or design interventions to promote comprehensive regenerative care in clinical practice, we first need to characterize those regenerative practices occurring today, patients expectations, perceptions and experiences about comprehensive regenerative care and determine the factors that promote and hinder their occurrence. Therefore, as exploratory work to inform the development of a comprehensive regenerative care clinic concept, we propose a qualitative study to explore patient perceptions of what it means to experience comprehensive regenerative care in the context of a clinical encounter.

   We hypothesize that the findings from this study will improve the care of patients with diabetes based on the concept of comprehensive regenerative care.  The findings from this study may also lead to better care plans that are congruent with patient goals and context, therefore leading to improvements in outcomes that matter to these patients.

5. A Study to Evaluate the Safety and Effectiveness of Crinecerfont in Adults with Classic Congenital Adrenal Hyperplasia

   Rochester, Minn.

   The purpose of this study is to evaluate the effectiveness of NBI-74788 (100 mg twice daily [bid]), compared with placebo, in reducing daily glucocorticoid dosage while maintaining adrenal androgen control, in reducing adrenal steroid levels following an initial 4-week treatment period, on clinical endpoints associated with supraphysiologic (greater than normal) glucocorticoid dosing, to evaluate plasma concentrations of NBI-74788 and metabolites, and to assess the safety and tolerability of NBI-74788.

6. Shared Decision Making in the Treatment of Obesity Through the Development of an Encounter Tool

   Rochester, Minn.

   The aim of this study is to develop, in close collaboration with stakeholders, an evidence-based decision aid to inform discussions regarding the treatment of obesity (Obesity Choice).

7. Pediatric Obesity Weight Evaluation Registry (POWER) Study

   Rochester, Minn.

   The main objective of this study is to establish a national pediatric obesity registry known as POWER (Pediatric Obesity Weight Evaluation Registry). This registry will contain clinical data from individual comprehensive pediatric weight management programs around the United States for overweight and obese youth.

8. A Study to Predict Recovery from Cushing Syndrome

   Rochester, Minn.

   The primary purpose of this study is to determine pre-surgical and post-surgical predictors of the duration and severity of glucocorticoid withdrawal in patients undergoing a curative surgery for cortisol excess.

9. A Study to Evaluate the Impact of Nutrition Education and Access to Nutritious Foods on Diabetes Control

   Mankato, Minn.

   The purpose of this study is to evaluate whether or not a 6 month supply (1 meal//day) of healthy food choices readily available in the patient's home and self management training including understanding of how foods impact diabetes, improved food choices and how to prepare those foods, improve glucose control.  In addition, it will evaluate whether or not there will be lasting behavior change modification after the program.

10. Cisplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery

    Rochester, Minn.

    This randomized phase II trial studies how well temozolomide and capecitabine work compared to standard treatment with cisplatin and etoposide in treating patients with neuroendocrine carcinoma of the gastrointestinal tract or pancreas that has spread to other parts of the body (metastatic) or cannot be removed by surgery. Drugs used in chemotherapy, such as temozolomide, capecitabine, cisplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Certain types of neuroendocrine carcinomas may respond better to treatments other than the current standard treatment of cisplatin and etoposide. It is not yet known whether temozolomide and capecitabine may work better than cisplatin and etoposide in treating patients with this type of neuroendocrine carcinoma, called non-small cell neuroendocrine carcinoma.